<DOC>
	<DOCNO>NCT02702492</DOCNO>
	<brief_summary>This study evaluate safety , tolerability , efficacy oral KPT-9274 treatment patient advance solid malignancy non-Hodgkin 's lymphoma ( NHL ) .</brief_summary>
	<brief_title>PAK4 NAMPT Patients With Solid Malignancies NHL ( PANAMA )</brief_title>
	<detailed_description>This first-in-human , multi-center , open-label clinical study separate Dose Escalation Expansion Phases ass preliminary safety , tolerability , efficacy KPT-9274 , dual inhibitor PAK4 NAMPT , patient advance solid malignancy ( include sarcoma , colon , lung , etc . ) NHL standard therapeutic option consider useful investigator exhaust .</detailed_description>
	<mesh_term>Niacin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<criteria>Advanced solid malignancy NHL standard therapeutic option consider useful exhaust . Must objective evidence progressive disease study entry . Advanced solid malignancy : Measureable disease define RECIST 1.1 . NHL : Measureable disease include target lesion ( ) define Lugano Classification initial evaluation staging . Must site disease amenable biopsy candidate biopsy . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤1 . Dose Expansion Phase ( KPT9274 + niacin ER cohort ) : Patient tumor NAPRT1 IDH1 tumor status must determine central laboratory prior enrollment . Life expectancy ≥3 month . Known central nervous system ( CNS ) disease leptomeningeal involvement , regardless response prior therapy . Major surgery within 4 week C1D1 . Active infection completion therapeutic antibiotic , antiviral , antifungal within one week prior C1D1 . Prophylactic antibiotic , antiviral antifungal permit . Known history Human Immunodeficiency Virus ( HIV ) ; HIV test require part study . Known , active hepatitis A , B , C infection ; know positive HCV RNA HBsAg ( HBV surface antigen ) . Significant diseased obstruct gastrointestinal tract uncontrolled vomit diarrhea could interfere absorption KPT9274 . Active peptic ulcer disease active gastrointestinal bleeds .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>PAK4</keyword>
	<keyword>KPT-9274</keyword>
	<keyword>Karyopharm</keyword>
	<keyword>NHL</keyword>
	<keyword>solid tumor</keyword>
</DOC>